FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3027663151> ?p ?o ?g. }

• W3027663151 endingPage "1230" @default.
• W3027663151 startingPage "1223" @default.
• W3027663151 abstract "Neratinib is an irreversible pan-HER tyrosine kinase inhibitor approved for extended adjuvant treatment in early-stage HER2-positive breast cancer based on the phase III ExteNET study. In that trial, in which no antidiarrheal prophylaxis was mandated, grade 3 diarrhea was observed in 40% of patients and 17% discontinued due to diarrhea. The international, open-label, sequential-cohort, phase II CONTROL study is investigating several strategies to improve tolerability.Patients who completed trastuzumab-based adjuvant therapy received neratinib 240 mg/day for 1 year plus loperamide prophylaxis (days 1-28 or 1-56). Sequential cohorts evaluated additional budesonide or colestipol prophylaxis (days 1-28) and neratinib dose escalation (DE; ongoing). The primary end point was the incidence of grade ≥3 diarrhea.Final data for loperamide (L; n = 137), budesonide + loperamide (BL; n = 64), colestipol + loperamide (CL; n = 136), and colestipol + as-needed loperamide (CL-PRN; n = 104) cohorts, and interim data for DE (n = 60; completed ≥six cycles or discontinued; median duration 11 months) are available. No grade 4 diarrhea was observed. Grade 3 diarrhea rates were lower than ExteNET in all cohorts and lowest in DE (L 31%, BL 28%, CL 21%, CL-PRN 32%, DE 15%). Median number of grade 3 diarrhea episodes was one; median duration per grade 3 episode was 1.0-2.0 days across cohorts. Most grade 3 diarrhea and diarrhea-related discontinuations occurred in month 1. Diarrhea-related discontinuations were lowest in DE (L 20%, BL 8%, CL 4%, CL-PRN 8%, DE 3%). Decreases in health-related quality of life did not cross the clinically important threshold.Neratinib tolerability was improved with preemptive prophylaxis or DE, which reduced the rate, severity, and duration of neratinib-associated grade ≥3 diarrhea compared with ExteNET. Lower diarrhea-related treatment discontinuations in multiple cohorts indicate that proactive management can allow patients to stay on neratinib for the recommended time period. CLINICALTRIALS.GOV: NCT02400476." @default.
• W3027663151 created "2020-05-29" @default.
• W3027663151 creator A5001373717 @default.
• W3027663151 creator A5003733456 @default.
• W3027663151 creator A5005226326 @default.
• W3027663151 creator A5005769474 @default.
• W3027663151 creator A5006306123 @default.
• W3027663151 creator A5009030272 @default.
• W3027663151 creator A5009477344 @default.
• W3027663151 creator A5010304248 @default.
• W3027663151 creator A5013531637 @default.
• W3027663151 creator A5021535454 @default.
• W3027663151 creator A5021913157 @default.
• W3027663151 creator A5023674071 @default.
• W3027663151 creator A5024038091 @default.
• W3027663151 creator A5024085564 @default.
• W3027663151 creator A5029214614 @default.
• W3027663151 creator A5030138461 @default.
• W3027663151 creator A5031887194 @default.
• W3027663151 creator A5034225982 @default.
• W3027663151 creator A5036327625 @default.
• W3027663151 creator A5041289938 @default.
• W3027663151 creator A5041940833 @default.
• W3027663151 creator A5042353769 @default.
• W3027663151 creator A5044108002 @default.
• W3027663151 creator A5044363769 @default.
• W3027663151 creator A5045301167 @default.
• W3027663151 creator A5046681315 @default.
• W3027663151 creator A5047113165 @default.
• W3027663151 creator A5047818279 @default.
• W3027663151 creator A5051758545 @default.
• W3027663151 creator A5053190272 @default.
• W3027663151 creator A5055811194 @default.
• W3027663151 creator A5058019518 @default.
• W3027663151 creator A5058592615 @default.
• W3027663151 creator A5059293529 @default.
• W3027663151 creator A5060575280 @default.
• W3027663151 creator A5062853695 @default.
• W3027663151 creator A5063794457 @default.
• W3027663151 creator A5064106888 @default.
• W3027663151 creator A5068059897 @default.
• W3027663151 creator A5072917229 @default.
• W3027663151 creator A5073677329 @default.
• W3027663151 creator A5074165276 @default.
• W3027663151 creator A5076336148 @default.
• W3027663151 creator A5078184758 @default.
• W3027663151 creator A5078290835 @default.
• W3027663151 creator A5079928617 @default.
• W3027663151 creator A5081735541 @default.
• W3027663151 creator A5083665059 @default.
• W3027663151 creator A5085464902 @default.
• W3027663151 creator A5087330004 @default.
• W3027663151 creator A5087341722 @default.
• W3027663151 creator A5090075138 @default.
• W3027663151 creator A5090188675 @default.
• W3027663151 date "2020-09-01" @default.
• W3027663151 modified "2023-10-10" @default.
• W3027663151 title "Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial" @default.
• W3027663151 cites W1990097438 @default.
• W3027663151 cites W2077880074 @default.
• W3027663151 cites W2087368293 @default.
• W3027663151 cites W2264000214 @default.
• W3027663151 cites W2768980003 @default.
• W3027663151 cites W2905295957 @default.
• W3027663151 cites W2912108694 @default.
• W3027663151 cites W2982496779 @default.
• W3027663151 cites W2995808512 @default.
• W3027663151 doi "https://doi.org/10.1016/j.annonc.2020.05.012" @default.
• W3027663151 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32464281" @default.
• W3027663151 hasPublicationYear "2020" @default.
• W3027663151 type Work @default.
• W3027663151 sameAs 3027663151 @default.
• W3027663151 citedByCount "57" @default.
• W3027663151 countsByYear W30276631512020 @default.
• W3027663151 countsByYear W30276631512021 @default.
• W3027663151 countsByYear W30276631512022 @default.
• W3027663151 countsByYear W30276631512023 @default.
• W3027663151 crossrefType "journal-article" @default.
• W3027663151 hasAuthorship W3027663151A5001373717 @default.
• W3027663151 hasAuthorship W3027663151A5003733456 @default.
• W3027663151 hasAuthorship W3027663151A5005226326 @default.
• W3027663151 hasAuthorship W3027663151A5005769474 @default.
• W3027663151 hasAuthorship W3027663151A5006306123 @default.
• W3027663151 hasAuthorship W3027663151A5009030272 @default.
• W3027663151 hasAuthorship W3027663151A5009477344 @default.
• W3027663151 hasAuthorship W3027663151A5010304248 @default.
• W3027663151 hasAuthorship W3027663151A5013531637 @default.
• W3027663151 hasAuthorship W3027663151A5021535454 @default.
• W3027663151 hasAuthorship W3027663151A5021913157 @default.
• W3027663151 hasAuthorship W3027663151A5023674071 @default.
• W3027663151 hasAuthorship W3027663151A5024038091 @default.
• W3027663151 hasAuthorship W3027663151A5024085564 @default.
• W3027663151 hasAuthorship W3027663151A5029214614 @default.
• W3027663151 hasAuthorship W3027663151A5030138461 @default.
• W3027663151 hasAuthorship W3027663151A5031887194 @default.
• W3027663151 hasAuthorship W3027663151A5034225982 @default.
• W3027663151 hasAuthorship W3027663151A5036327625 @default.
• W3027663151 hasAuthorship W3027663151A5041289938 @default.

• next